After therapy with IVIG, the ratio of CD4+/CD8+ T and the percentage of CD4+CD45RA+ T cells increased, while the percentage of CD8+ T, CD4+CD45RO+ T, and CD19+ B cells significantly declined in the AIDP group. The gene discussed is CD19; the disease is Guillain-Barre syndrome, familial.